Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St set for higher open as AI stocks rise, oil slides
- Oil prices slide to 11-day low on hopes of US-Iran diplomacy, Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- Streamflation drives 39% of Americans to cancel streaming in 6 months
- Wall St set for higher open as AI stocks rise, oil slides
Arbutus Biopharma (ABUS) Reports In-Line Q3 EPS; Cash and Cash Equivalents of 151.9M
November 4, 2021 7:45 AM EDTArbutus Biopharma (NASDAQ: ABUS) reported Q3 EPS of ($0.24), in-line with the analyst estimate of ($0.24). Revenue for the quarter came in at $3.34 million versus the consensus estimate of $2.38 million.
For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.
... More